Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3991318 | Journal of Thoracic Oncology | 2007 | 4 Pages |
Abstract
Statistically significant advantages demonstrated in a single phase III clinical trial may have only a modest and transient impact on American oncologists' prescribing behaviors. Factors other than the phase III trial results themselves play a role in the likelihood that prescribing behavior will evolve over time. Corroborating trial data among unambiguously relevant populations will be necessary to stimulate a change in standard treatment paradigms.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Mark R. MD, Afshin MD, Lalitha MS, MBA, Laura BS, Joanne RN, OCN, Michele MPH, Richard MD,